Figure 3: Both HDAC6 and SIRT2 inhibitors prevent LRRK2 Roc-COR mutant filamentous structures. | Nature Communications

Figure 3: Both HDAC6 and SIRT2 inhibitors prevent LRRK2 Roc-COR mutant filamentous structures.

From: Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations

Figure 3

(a) HEK293 cells were transfected with acGFP1-tagged LRRK2 variants (green) as indicated. Twenty-four hours after transfection, the cells were treated with vehicle (Ctrl), 2 μM tubastatin-A (TubA) or 5 μM AGK2 for 4 h. After treatment, the cells were fixed and processed for immunostaining using anti-acetylated α-tubulin antibody (red). Scale bar, 10 μm; zoom, 5 μm. (b) The percentage of vehicle (Ctrl), TubA and AGK2-treated HEK293 cells exhibiting filamentous LRRK2 was quantified (mean±s.e.m., zero values are indicated (0)). **P<0.01, ****P<0.0001, two-way analysis of variance followed by Fisher’s least significant difference post hoc test. N (coverslips counted, ~50 cells per coverslip, from four experiments)=WT, 5; WT+TubA, 5; WT+AGK2, 5; Y1699C, 13; Y1699C+TubA, 4; Y1699C+AGK2, 9; R1441C, 15; R1441C+TubA, 5; R1441C+AGK2, 9.

Back to article page